Copy
Email not displaying correctly? View it in your browser   
PlantForm AGM highlights

PlantForm has made significant progress in research and development projects over the last year and has realigned its product pipeline to respond to market developments, Don Stewart, President and CEO, reported at the Company’s annual general meeting in Toronto Sept. 20.
Biosimilar Lucentis® (ranibizumab), a treatment for age-related macular degeneration, is now the Company’s lead drug candidate for North American and European markets.

The company is seeking a co-development partner to advance its biosimilar Herceptin® (trastuzumab) product for a novel indication, following research at The Hospital for Sick Children (SickKids) in Toronto that shows trastuzumab accelerates nerve regeneration in cases of acute trauma. PlantForm has licensed the intellectual property rights from SickKids to commercialize trastuzumab for this purpose.
The company is also continuing development of biosimilar Humira® (adalimumab) for rheumatoid arthritis for the Brazilian and South American markets.

A wholly-owned subsidiary, AntoXa Corporation, has been created to develop the company’s innovative medical countermeasure program, which includes drug candidates that protect against exposure to ricin, sarin and Ebola Sudan (see more about AntoXa below).

The company has submitted 3 new patents and has received notice of issuance of the patent  “Methods of  Improving the Therapeutic Efficacy and Utility of Antibody Fragments” in the EU.

“We are pleased with the progress made in our research and development projects over the last year as we continue to advance and demonstrate the capabilities of our vivoXPRESS® platform technology to deliver important biologic drugs for novel indications and new markets," Stewart said.
 
 
Introducing AntoXa: Plant-made biopharmaceuticals for a safer world
PlantForm has established AntoXa Corporation as a wholly-owned subsidiary to develop medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as from outbreaks of naturally occurring infectious diseases.

AntoXa will initially focus on producing countermeasures for ricin, sarin, soman and Ebola Sudan, as well as other biodefense therapeutics, using PlantForm’s vivoXPRESS® biopharmaceutical manufacturing platform, said Don Stewart, President and CEO of PlantForm and AntoXa.

“Establishing AntoXa allows the PlantForm group of companies to focus on different areas of expertise:  AntoXa on medical countermeasures; PlantForm Canada on innovative, biosimilar and biobetter opportunities for North America and Europe; and PlantForm do Brasil (PlantPraxis) on biosimilar and biobetter opportunities for Latin America,” Stewart said.

“AntoXa also provides a vehicle for investors who wish to focus on medical countermeasure opportunities, and allows the company to develop a group of employees with the specialty expertise to address the civilian and military needs for medical countermeasures.”
 



Pilot production facility under construction in Brazil
Construction is under way on a state-of-the-art biopharmaceutical lab and pilot production facility in Rio de Janeiro that will support the development of key biosimilar and biobetter protein drugs for the Brazilian market, through a joint venture between PlantForm and Brazil-based Axis Biotec Brasil.

The new laboratory and manufacturing facility, supported by funding from Finep (Brazilian Funding Agency for Studies and Projects) is expected to be completed by the end of 2017.
 
It marks a major milestone in an initiative first announced last year, when Finep provided a US$1-million grant to Silvestre Labs, part of the Axis Biotec Brasil group of companies. The joint venture, called PlantPraxis, will first develop a biosimilar version of adalimumab (Humira®) for rheumatoid arthritis and other inflammatory disorders using PlantForm’s vivoXPRESS® manufacturing platform.

The new facility will be operational in 2018, with several additional biological targets in the pipeline. The long-term goal is to establish a commercial scale manufacturing plant in Brazil to serve the South American market, and a facility in Canada for the North American and European markets.

Also see Plant-Based Biosimilar Development Takes Root in Brazil, Biosimilar Development (Aug. 9, 2017).
 


Share our newsletter:
   

Keep in touch:
Get regular updates on our activities and industry news by following PlantForm on Twitter, LinkedIn and Facebook:
 
Facebook page - PlantForm
September 2017

Biosimilar news

The FDA approved the first biosimilar drug for the treatment of cancer, a biosimilar to Avastin®, on Sept. 14. Read more.



Trastuzumab for nerve regeneration

CEO Don Stewart will present on trastuzumab as nerve regeneration drug for acute trauma patients at Defense Innovation Technology Acceleration Challenges Oct. 3.
PlantForm is collaborating with researchers at The Hospital for Sick Children (SickKids) in Toronto to develop the use of plant-produced trastuzumab for this novel indication.
 

RESI conference Nov. 15

AntoXa will participate in a trade mission, hosted by the Export Services Branch of the Ontario Ministry of International Trade, to the Redefining Early Stage Investments (RESI) Conference Nov. 15 in New York City.

 

New publication

Dr. Mike McLean, PlantForm’s Director of Research has published Trastuzumab Made in Plants Using vivoXPRESS® Platform Technology in the Journal of Drug Design and Research (May 2017). In this paper, data are presented demonstrating that PlantForm's scientists can engineer the glycomodification process that takes place in plants to improve the effectiveness of plant-made therapeutic glycoproteins, such as antibodies. 

 

Management Team

Don Stewart, PhD
President & CEO

David Cayea, BA
Chief Operating Officer

Ron Hosking, CA
Chief Financial Officer

J. Christopher Hall, PhD
Chief Scientific Officer

Doug Cossar, PhD
Vice-President, Research

Craig Binnie, PhD
Vice-President, Drug Development


Board of Directors

Warren Whitehead, MBA
Chairman of the Board of Directors
Former CFO, Arius Research

Mark Goldberg, PhD, DABT, C.Dir.
Founder and former CEO, GlobalTox

James Rae
President and Founder, Remedis Consulting

J. Christopher Hall, PhD
CSO, PlantForm Corp.

Don Stewart, PhD
President & CEO, PlantForm Corp.


 
PlantForm is a Canadian company focused on providing
low-cost therapeutic antibody drugs that fight cancer and other critical illnesses.

Our mailing address is:
1920 Yonge St, Suite 200
Toronto, Ontario
M4S 3E2  CANADA
For more information, contact:
Don Stewart
President & CEO
416-452-7242

Email Marketing Powered by MailChimp






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
PlantForm Corporation · 1920 Yonge Street, Suite 200 · Toronto, Ontario M4S 3E2 · Canada

Email Marketing Powered by MailChimp